Jennison Associates LLC Sells 108,848 Shares of Corteva, Inc. $CTVA

Key Points

• Jennison Associates cut its stake in Corteva by 38.7%, selling 108,848 shares in Q4 and retaining 172,501 shares valued at about $11.56 million at quarter-end.
• Analyst sentiment is broadly positive with a MarketBeat consensus of "Moderate Buy" and an average price target of $86.38, while recent price-target raises include Deutsche Bank to $90 and UBS to $88 amid some mixed rating changes.
• Corteva set FY2026 EPS guidance of 3.450–3.700 (analysts average 3.62) and announced a quarterly dividend of $0.18 ($0.72 annual, ~0.9% yield) with an ex-dividend date of June 1 and payment on June 15.

Jennison Associates LLC lessened its holdings in Corteva, Inc. (NYSE:CTVA - Free Report) by 38.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 172,501 shares of the company's stock after selling 108,848 shares during the period. Jennison Associates LLC's holdings in Corteva were worth $11,563,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Chilton Capital Management LLC lifted its holdings in Corteva by 18.1% during the third quarter. Chilton Capital Management LLC now owns 445,350 shares of the company's stock valued at $30,119,000 after purchasing an additional 68,380 shares during the last quarter. Drummond Knight Asset Management Pty Ltd bought a new position in shares of Corteva in the fourth quarter worth approximately $25,713,000. TriaGen Wealth Management LLC bought a new position in shares of Corteva in the third quarter worth approximately $4,284,000. Truist Financial Corp increased its position in shares of Corteva by 4.5% in the third quarter. Truist Financial Corp now owns 321,913 shares of the company's stock worth $21,771,000 after purchasing an additional 13,910 shares during the last quarter. Finally, New York State Teachers Retirement System grew its position in Corteva by 4.5% during the third quarter. New York State Teachers Retirement System now owns 551,389 shares of the company's stock valued at $37,290,000 after acquiring an additional 23,548 shares during the last quarter. Institutional investors own 81.54% of the company's stock.

Analysts Set New Price Targets

CTVA has been the topic of several recent analyst reports. UBS Group raised their target price on shares of Corteva from $80.00 to $88.00 and gave the stock a "neutral" rating in a report on Thursday, April 9th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Corteva from $85.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, February 5th. JPMorgan Chase & Co. cut shares of Corteva from an "overweight" rating to a "neutral" rating and raised their target price for the stock from $75.00 to $77.00 in a report on Thursday, February 5th. Rothschild & Co Redburn raised their price target on Corteva from $80.00 to $90.00 and gave the stock a "neutral" rating in a research note on Wednesday. Finally, Zacks Research lowered Corteva from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 20th. Fourteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Corteva has a consensus rating of "Moderate Buy" and an average price target of $86.38.

Insider Buying and Selling

In related news, insider Brian Titus sold 8,311 shares of Corteva stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the sale, the insider directly owned 8,090 shares in the company, valued at approximately $619,289.50. This trade represents a 50.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.15% of the company's stock.

Corteva Stock Performance

Shares of Corteva stock opened at $80.97 on Friday. The company has a current ratio of 1.43, a quick ratio of 0.96 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $54.36 billion, a P/E ratio of 51.24, a P/E/G ratio of 2.77 and a beta of 0.59. The business has a fifty day simple moving average of $80.39 and a two-hundred day simple moving average of $72.12. Corteva, Inc. has a 12 month low of $60.53 and a 12 month high of $85.63.

Corteva (NYSE:CTVA - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 EPS for the quarter, meeting the consensus estimate of $0.22. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The business had revenue of $3.91 billion during the quarter, compared to analyst estimates of $4.23 billion. During the same quarter last year, the firm posted $0.32 earnings per share. The company's revenue for the quarter was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, equities analysts forecast that Corteva, Inc. will post 3.62 earnings per share for the current fiscal year.

Corteva Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 15th. Investors of record on Monday, June 1st will be issued a $0.18 dividend. This represents a $0.72 annualized dividend and a yield of 0.9%. The ex-dividend date is Monday, June 1st. Corteva's dividend payout ratio (DPR) is presently 45.57%.

About Corteva

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.